Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Osteoarthritis and Bone Disorders

Denosumab Does Not Stimulate Early Bone Formation

Reuters Staff  |  

NEW YORK (Reuters Health)—The early elevation in intact parathyroid hormone (iPTH) seen with denosumab treatment is not associated with increased bone formation, according to research from Eli Lilly and Company. Denosumab is a member of the anticatabolic/antiresorptive class of drugs used to treat osteoporosis; iPTH levels are increased in the first several months after denosumab…

Amgen, UCB Say Osteoporosis Drug Meets Main Goal in Late-Stage Trial

Reuters Staff  |  

(Reuters)—Amgen Inc. and Belgium-based UCB SA said on Monday that their osteoporosis drug met all the primary endpoints by reducing the incidence of new vertebral fracture in postmenopausal women with osteoporosis in a late-stage study. The topline results, from a Fracture study in postmenopausal women with osteoporosis (FRAME), showed that the drug romosozumab met a…

VA Musculoskeletal Education Pilot Program Helps PCPs Treat Patients

Arthritis Care & Research  |  

To improve access to quality of care for patients with osteoarthritis and other musculoskeletal pain, the U.S. Department of Veterans Affairs (VA) launched a continuing education program designed to strengthen the musculoskeletal knowledge and skills of primary care providers (PCPs). In the program’s initial trial in 2012, 19 physicians were trained on exams, treatments and joint injections. Two years after course completion, some participants increased the number of intraarticular corticosteroid injections at their clinics without needing to refer patients to specialists…

Overscreening, Overtreatment of Osteoporosis Common

Anne Harding  |  

NEW YORK (Reuters Health)—Too many women who aren’t at risk for osteoporosis are being screened for the disease, and too many women who don’t need osteoporosis treatment are getting it, new research suggests. “In our health system the overtreatment of osteoporosis was common, and this was partly due to the fact that a lot of…

People with Schizophrenia at Higher Risk of Osteoporosis

David Douglas  |  

NEW YORK (Reuters Health)—Pooled data indicate that bone mineral density (BMD) is significantly lower in patients with schizophrenia than in healthy controls, according to Taiwanese researchers. Dr. Ping-Tao Tseng tells Reuters Health by email that the “evidence indicates the importance of further screening for the risk of osteoporosis in young-aged schizophrenic patients . . ….

Combo Drug for Arthritis & Hypertension Meets Goal in Phase 3 Study

Rosmi Shaji  |  

(Reuters)—Kitov Pharmaceuticals Holdings Ltd. said on Tuesday its lead drug, KIT-302, met the main goal of a late-stage study, reducing pain without increasing the risk of heart diseases in patients with osteoarthritis. Israel-based Kitov says its drug does not need to be labeled with health warnings, but will instead say it reduces the risk of…

How to Manage Polymyalgia Rheumatica

  |  

Recognizing the need to provide guidance on the current disparate management of polymyalgia rheumatica (PMR), the American College of Rheumatology (ACR), in collaboration with the European League Against Rheumatism (EULAR), recently published the first international set of recommendations for the screening, treatment and management of PMR.1,2 Specifically, the recommendations offer guidance on the use of…